Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.38 |
| ▸ | LGALS8 | O00214 | 3/20 | 0.38 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.38 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | AMY2A | P04746 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | TYR | P14679 | 1/20 | 0.34 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24004413 | 1.00 | L3MBTL1 (0.53) | L3MBTL1MAPTAMY1ALGALS8LGALS3 | |
| SCHEMBL13034058 | 1.00 | L3MBTL1 (0.53) | L3MBTL1MAPTAMY1ALGALS8LGALS3 | |
| SCHEMBL824856 | 0.94 | L3MBTL1 (0.48) | L3MBTL1MAPTAMY1ALGALS8LGALS3 | |
| SCHEMBL24702744 | 0.87 | L3MBTL1 (0.67) | L3MBTL1MAPTPOLBMEN1KMT2A | |
| SCHEMBL26192078 | 0.87 | L3MBTL1 (0.67) | L3MBTL1MAPTPOLBMEN1KMT2A | |
| SCHEMBL26192479 | 0.87 | L3MBTL1 (0.67) | L3MBTL1MAPTPOLBMEN1KMT2A | |
| SCHEMBL19430679 | 0.87 | L3MBTL1 (0.67) | L3MBTL1MAPTPOLBMEN1KMT2A | |
| SCHEMBL24702743 | 0.87 | L3MBTL1 (0.67) | L3MBTL1MAPTPOLBMEN1KMT2A | |
| SCHEMBL13073219 | 0.87 | L3MBTL1 (0.48) | L3MBTL1MAPTAMY1ALGALS8LGALS3 | |
| SCHEMBL18823595 | 0.86 | L3MBTL1 (0.44) | L3MBTL1MAPTAMY1ALGALS8LGALS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210347826-A1 | CYCLIC PEPTIDE COMPOUNDS AND METHODS OF USE THEREOF | MODULATION THERAPEUTICS, INC. | 2021-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210347826-A1 | CYCLIC PEPTIDE COMPOUNDS AND METHODS OF USE THEREOF | VIP, IAPP, SCTR | L3MBTL1 531/4885MAPT 4775/4885AMY1A 2855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.